



## Glaukos Announces Participation in 29th Annual ROTH Conference

2017-02-27

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 29<sup>th</sup> Annual ROTH Conference on Monday, March 13, 2017, at 9:30 a.m. PDT in Laguna Niguel, California.

A live audio webcast for this event will be available in the Investors section of the Glaukos website at <http://investors.glaukos.com> and will be archived for 90 days.

### **About Glaukos**

Glaukos ([www.glaukos.com](http://www.glaukos.com)) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world's leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the *iStent*<sup>®</sup>, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the *iStent*, measuring 1.0 mm long and 0.33 mm wide, is the smallest medical device ever approved by the FDA.

View source version on  
businesswire.com: <http://www.businesswire.com/news/home/20170227005212/en/>

Source: Glaukos Corporation

Glaukos Corporation

Sheree Aronson

VP, Investor Relations

(949) 367-9600 ext 371

[saronson@glaukos.com](mailto:saronson@glaukos.com)